Free Trial

Petros Pharmaceuticals Q1 2023 Earnings Report

Petros Pharmaceuticals logo
$0.08 +0.01 (+21.56%)
As of 04/1/2025 04:00 PM Eastern

Petros Pharmaceuticals EPS Results

Actual EPS
-$0.66
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Petros Pharmaceuticals Revenue Results

Actual Revenue
$2.52 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Petros Pharmaceuticals Announcement Details

Quarter
Q1 2023
Time
N/A

Conference Call Resources

Remove Ads

Petros Pharmaceuticals Earnings Headlines

Trump to unlock 15-figure fortune for America (May 3rd) ?
We were shown this map by former Presidential Advisor, Jim Rickards, one of the most politically connected men in America. Rickards has spent his fifty-year career in the innermost circles of the U.S. government and banking. And he believes Trump could soon release this frozen asset to the public.
Petros Pharmaceuticals prices 40M shares at 24c in public offering
See More Petros Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Petros Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Petros Pharmaceuticals and other key companies, straight to your email.

About Petros Pharmaceuticals

Petros Pharmaceuticals (NASDAQ:PTPI), a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, penile injections, PreBoost, VenoSeal, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York.

View Petros Pharmaceuticals Profile

More Earnings Resources from MarketBeat